氨己烯酸片(喜保宁)的作用及价格

It is a drug used to treat epilepsy and infantile spasms. It was developed in the 1980s. In 1989, vigabatrin tablets (vigabatrin) were approved for treatment in the UK. On August 21, 2009, the U.S. FDA approved Vigabatrin Tablets (Vigabatrin) as a monotherapy for pediatric patients aged 1 month to 2 years old. Its potential benefits for infantile spasms outweigh the potential risk of vision loss, and as an adjuvant (additional) treatment (CPS) for adult patients with refractory complex partial epilepsy. On January 16, 2019, the FDA approved the launch of a generic version of vigabatrin.

Vigabatrin is an analog of gamma-aminobutyric acid (GABA). It can specifically bind to GABA aminotransferase and irreversibly, leading to an increase in the concentration of GABA in the brain, thereby exerting anti-epileptic effects. Clinically, vigabatrin tablets (vigabatrin) are used to treat epilepsy in which other anti-epileptic drugs are ineffective, especially partial seizures; vigabatrin tablets (vigabatrin) can also treat infantile spasms (West syndrome, West syndrome).

It is understood that vigabatrin tablets are only available in a few countries, and the vigabatrin tablets (vigabatrin) produced by Sanofi in France are cost-effective. Its specifications are 500 mg

The treatment effect is significant, but taking this drug for treatment will also produce certain side effects or adverse reactions. Before receiving treatment with vigabatrin tablets, patients should go to the hospital for a detailed examination and strictly take medication according to the doctor's diagnosis and treatment recommendations. The use of vigabatrin tablets (vigabatrin) should be done under the guidance of an epilepsy expert or a child neurologist. Reactions after taking the medication should be reported to the doctor promptly.

Recommended related hot articles: /newsDetail/84564.html